Cyltezo® (adalimumab-adbm) – First interchangeable biosimilar to Humira
October 18, 2021 - The FDA announced the approval of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), as the first interchangeable biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
